Analytical and Bioanalytical Chemistry

, Volume 403, Issue 9, pp 2715–2724 | Cite as

Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing

  • Ines Möller
  • Andreas Thomas
  • Hans Geyer
  • Wilhelm Schänzer
  • Mario Thevis
Original Paper

Abstract

As recently reported, dried blood spot (DBS) analysis is an advantageous technique for doping control purposes due to the minimal invasive sample collection, the simple and economic manner, as well as the low susceptibility to manipulation. Its general applicability to the sports drug testing arena has been shown for analytes of various substance classes, all of which comprise exclusively low molecular mass compounds. The aim of the present study was to investigate whether the technique of DBS analysis is applicable also to (pegylated) peptides with relevance for doping controls. As target analyte, peginesatide (Omontys, Hematide), a recently approved pegylated erythropoietin-mimetic peptide of approximately 45 kDa, tested for the treatment of anaemia in patients with renal failure, was chosen, which has been prohibited in elite sports due to its assumed endurance enhancing effects. Therefore, a detection method for peginesatide employing DBS was developed based on extraction, proteolytic digestion and cation-exchange purification followed by liquid chromatography–tandem mass spectrometry analysis. Eventually, the assay was validated for qualitative purposes and proved to be specific, sensitive (limit of detection, 10 ng/mL) and precise (relative standard deviations below 18 %), demonstrating the general suitability of DBS analysis in sports drug testing also for (pegylated) peptides.

Keywords

Peginesatide Omontys Hematide Doping Erythropoiesis-stimulating agents Q Exactive 

References

  1. 1.
    Guthrie R, Susi A (1963) A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338–343Google Scholar
  2. 2.
    Millership JS (2011) Microassay of drugs and modern measurement techniques. Bioanalysis 3:197–205CrossRefGoogle Scholar
  3. 3.
    Edelbroek PM, van der Heijden J, Stolk LM (2009) Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31:327–336CrossRefGoogle Scholar
  4. 4.
    Burnett JE (2011) Dried blood spot sampling: practical considerations and recommendation for use with preclinical studies. Bioanalysis 3:1025–1030CrossRefGoogle Scholar
  5. 5.
    Pandya HC, Spooner N, Mulla H (2011) Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis 3:779–786CrossRefGoogle Scholar
  6. 6.
    Patel P, Mulla H, Tanna S, Pandya H (2010) Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child 95:484–487CrossRefGoogle Scholar
  7. 7.
    Parker SP, Cubitt WD (1999) The use of the dried blood spot sample in epidemiological studies. J Clin Pathol 52:633–639CrossRefGoogle Scholar
  8. 8.
    McDade TW, Williams S, Snodgrass JJ (2007) What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 44:899–925CrossRefGoogle Scholar
  9. 9.
    Li W, Tse FL (2010) Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr 24:49–65CrossRefGoogle Scholar
  10. 10.
    Wilhelm AJ, den Burger JC, Vos RM, Chahbouni A, Sinjewel A (2009) Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1595–1598CrossRefGoogle Scholar
  11. 11.
    Li W, Williams SM, Smith HT, Tse FL (2011) Quantitative analysis of NIM811, a cyclophilin inhibitor, in human dried blood spots using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2376–2382CrossRefGoogle Scholar
  12. 12.
    Ewles MF, Turpin PE, Goodwin L, Bakes DM (2011) Validation of a bioanalytical method for the quantification of a therapeutic peptide, ramoplanin, in human dried blood spots using LC-MS/MS. Biomed Chromatogr 25:995–1002CrossRefGoogle Scholar
  13. 13.
    Kehler JR, Bowen CL, Boram SL, Evans CA (2010) Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS. Bioanalysis 2:1461–1468CrossRefGoogle Scholar
  14. 14.
    deWilde A, Sadilkova K, Sadilek M, Vasta V, Hahn SH (2008) Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography-tandem mass spectrometry: application to newborn screening. Clin Chem 54:1961–1968CrossRefGoogle Scholar
  15. 15.
    Kehler JR, Akella N, Citerone D, Szapacs M (2011) Application of DBS for the quantitative assessment of a protein biologic using on-card digestion LC-MS/MS or immunoassay. Bioanalysis 3:2283–2290CrossRefGoogle Scholar
  16. 16.
    Sleczka BG, D’Arienzo CJ, Tymiak AA, Olah TV (2012) Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery. Bioanalysis 4:29–40CrossRefGoogle Scholar
  17. 17.
    Wong P, Pham R, Bruenner BA, James CA (2010) Increasing efficiency for dried blood spot analysis: prospects for automation and simplified sample analysis. Bioanalysis 2:1787–1789CrossRefGoogle Scholar
  18. 18.
    Thomas A, Geyer H, Guddat S, Schänzer W, Thevis M (2011) Dried blood spots (DBS) for doping control analysis. Drug Test Analysis 3:806–813CrossRefGoogle Scholar
  19. 19.
    El Ezzi AA, El-Saidi MA, Kuddus RH (2010) Long-term stability of thyroid hormones and DNA in blood spots kept under varying storage conditions. Pediatr Int 52:631–639CrossRefGoogle Scholar
  20. 20.
    Thomas A, Geyer H, Schänzer W, Crone C, Kellmann M, Moehring T, Thevis M (2012) Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal Bioanal Chem. doi:10.1007/s00216-011-5655-2
  21. 21.
    Peng SH, Segura J, Farre M, de la Torre X (2000) Oral testosterone administration detected by testosterone glucuronidation measured in blood spots dried on filter paper. Clin Chem 46:515–522Google Scholar
  22. 22.
    WADA (2011) The 2012 prohibited list—international standard. WADA (World Anti-Doping Agency). Available from: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf. Accessed December 2011
  23. 23.
    Macdougall IC (2008) Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 9:1034–1047Google Scholar
  24. 24.
    Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y (2012) Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica. doi:10.3109/00498254.2011.649310
  25. 25.
    Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:1848–1855CrossRefGoogle Scholar
  26. 26.
    Macdougall IC (2012) New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 59:444–451CrossRefGoogle Scholar
  27. 27.
    Affymax (2011) Affymax and Takeda Announce the Submission of a New Drug Application for Peginesatide for the Treatment of Anemia Associated with Chronic Renal Failure in Patients on Dialysis. Affymax Inc. Available from: http://www.investors.affymax.com/releasedetail.cfm?ReleaseID=581773. Accessed January 2012
  28. 28.
    FDA (2012) FDA approves Omontys to treat anemia in adult patients on dialysis. U.S. Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm. Accessed March 2012
  29. 29.
    Möller I, Thomas A, Geyer H, Schänzer W, Thevis M (2011) Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun Mass Spectrom 25:2115–2123CrossRefGoogle Scholar
  30. 30.
    Leuenberger M, Saugy J, Mortensen RB, Schatz P, Giraud S, Saugy M (2011) Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. Forensic Sci Int 213:15–19CrossRefGoogle Scholar
  31. 31.
    Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ (2008) Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol 48:43–52CrossRefGoogle Scholar
  32. 32.
    ICH (2005) Validation of analytical procedures: text and methodology Q2(R1). ICH (International Conference on Harmonisation). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed January 2012
  33. 33.
    Youhnovski N, Bergeron A, Furtado M, Garofolo F (2011) Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun Mass Spectrom 25:2951–2958CrossRefGoogle Scholar
  34. 34.
    Patel P, Tanna S, Mulla H, Kairamkonda V, Pandya H, Lawson G (2010) Dexamethasone quantification in dried blood spot samples using LC-MS: the potential for application to neonatal pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 878:3277–3282CrossRefGoogle Scholar
  35. 35.
    Bonfiglio R, King RC, Olah TV, Merkle K (1999) The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 13:1175–1185CrossRefGoogle Scholar
  36. 36.
    Affymax (2011) Efficacy and safety of Hematide™ injection in the treatment of anemia in patients with chronic kidney disease. U.S. National Library of Medicine. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00314795?term=hematide&rank=4. Accessed January 2012
  37. 37.
    GE Healthcare (2010) FTA™ DMPK Card Selection. General Electric Company. Available from: http://www.whatman.com/References/FTA%20DMPK%20Card%20Selection%20Guide.pdf. Accessed January 2012
  38. 38.
    Vergouwen PC, Collee T, Marx JJ (1999) Haematocrit in elite athletes. Int J Sports Med 20:538–541CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ines Möller
    • 1
  • Andreas Thomas
    • 1
  • Hans Geyer
    • 1
  • Wilhelm Schänzer
    • 1
  • Mario Thevis
    • 1
  1. 1.Institute of Biochemistry, Center for Preventive Doping ResearchGerman Sport University CologneCologneGermany

Personalised recommendations